Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yeo-Jin Song, Seoung Wan Nam, Chang Hee Suh, Jung Yoon Choe & Dae Hyun Yoo. (2023) Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview. Expert Opinion on Drug Metabolism & Toxicology 19:11, pages 751-768.
Read now
Read now
Nemanja Damjanov, Nana Kirvalidze, Nana Kurashvili, Fausto Berti, Matjaz Steiger, Joanna Sobierska, Eric Guenzi, Hendrik Otto, Abid Sattar, Halimu N. Haliduola, Elin Edwald & Heimo Stroissnig. (2023) Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringe. Expert Opinion on Biological Therapy 23:8, pages 781-789.
Read now
Read now
Christopher Wynne, Christian Schwabe, Heimo Stroissnig, Roshan Dias, Joanna Sobierska, Eric Guenzi, Hendrik Otto, Abid Sattar, Halimu N Haliduola, Elin Edwald & Fausto Berti. (2023) A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adults. Expert Opinion on Biological Therapy 23:8, pages 773-780.
Read now
Read now
Oliver von Richter, Terry O’Reilly, Davide Guerrieri, Jamie Fan, Constanze Fey, Steven Schussler, Fabricio Furlan & Lena Lemke. (2023) GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar. Expert Opinion on Biological Therapy 23:8, pages 749-758.
Read now
Read now
Articles from other publishers (2)
Halimu N. Haliduola, Fausto Berti, Heimo Stroissnig, Eric Guenzi, Hendrik Otto, Abid Sattar & Ulrich Mansmann. (2022) Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study. BMC Medical Research Methodology 22:1.
Crossref
Crossref
Connie Kang. (2022) AVT02: An Adalimumab Biosimilar. Clinical Drug Investigation 42:10, pages 875-878.
Crossref
Crossref